Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia

Mehdi Hamadani, Farrukh T. Awan

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades. However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post-remission consolidation strategy among various risk groups. We are not only beginning to realize the pitfalls of a 'one-fits-all' approach with intensive, cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, 'targeted' therapy for each AML patient based on unique molecular features of disease remains a daunting goal yet one that we can now begin to envision. Hypothesis-based study designs-from preclinical/ laboratory experiments to phase-I and subsequent efficacy trials - provide the foundation for advances in the diagnosis, risk stratification, and treatment for patients with AML. Here we critically review the literature for the management of AML, try to give recommendations regarding the appropriate induction and remission strategy, clarify the role of stem cell transplantation and discuss novel agents on the horizon.

Original languageEnglish (US)
Pages (from-to)3-12
Number of pages10
JournalHematological Oncology
Volume28
Issue number1
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Remission Induction
Acute Myeloid Leukemia
Drug Therapy
Translational Medical Research
Cytarabine
Stem Cell Transplantation
Genomics
Reward
Cytogenetics
Therapeutics
Recognition (Psychology)

Keywords

  • Acute myeloid leukaemia
  • Cytarabine
  • Daunorubicin
  • Hematopoietic stem cell transplantation
  • HIDAC

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. / Hamadani, Mehdi; Awan, Farrukh T.

In: Hematological Oncology, Vol. 28, No. 1, 01.03.2010, p. 3-12.

Research output: Contribution to journalReview article

@article{c4b3670635344d97ad49e9e028bf33c7,
title = "Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia",
abstract = "Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades. However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post-remission consolidation strategy among various risk groups. We are not only beginning to realize the pitfalls of a 'one-fits-all' approach with intensive, cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, 'targeted' therapy for each AML patient based on unique molecular features of disease remains a daunting goal yet one that we can now begin to envision. Hypothesis-based study designs-from preclinical/ laboratory experiments to phase-I and subsequent efficacy trials - provide the foundation for advances in the diagnosis, risk stratification, and treatment for patients with AML. Here we critically review the literature for the management of AML, try to give recommendations regarding the appropriate induction and remission strategy, clarify the role of stem cell transplantation and discuss novel agents on the horizon.",
keywords = "Acute myeloid leukaemia, Cytarabine, Daunorubicin, Hematopoietic stem cell transplantation, HIDAC",
author = "Mehdi Hamadani and Awan, {Farrukh T.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1002/hon.915",
language = "English (US)",
volume = "28",
pages = "3--12",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia

AU - Hamadani, Mehdi

AU - Awan, Farrukh T.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades. However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post-remission consolidation strategy among various risk groups. We are not only beginning to realize the pitfalls of a 'one-fits-all' approach with intensive, cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, 'targeted' therapy for each AML patient based on unique molecular features of disease remains a daunting goal yet one that we can now begin to envision. Hypothesis-based study designs-from preclinical/ laboratory experiments to phase-I and subsequent efficacy trials - provide the foundation for advances in the diagnosis, risk stratification, and treatment for patients with AML. Here we critically review the literature for the management of AML, try to give recommendations regarding the appropriate induction and remission strategy, clarify the role of stem cell transplantation and discuss novel agents on the horizon.

AB - Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades. However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post-remission consolidation strategy among various risk groups. We are not only beginning to realize the pitfalls of a 'one-fits-all' approach with intensive, cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, 'targeted' therapy for each AML patient based on unique molecular features of disease remains a daunting goal yet one that we can now begin to envision. Hypothesis-based study designs-from preclinical/ laboratory experiments to phase-I and subsequent efficacy trials - provide the foundation for advances in the diagnosis, risk stratification, and treatment for patients with AML. Here we critically review the literature for the management of AML, try to give recommendations regarding the appropriate induction and remission strategy, clarify the role of stem cell transplantation and discuss novel agents on the horizon.

KW - Acute myeloid leukaemia

KW - Cytarabine

KW - Daunorubicin

KW - Hematopoietic stem cell transplantation

KW - HIDAC

UR - http://www.scopus.com/inward/record.url?scp=77950870037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950870037&partnerID=8YFLogxK

U2 - 10.1002/hon.915

DO - 10.1002/hon.915

M3 - Review article

C2 - 19645073

AN - SCOPUS:77950870037

VL - 28

SP - 3

EP - 12

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -